161MO Efficacy and safety of relugolix in Asian men with advanced prostate cancer (APC): A subgroup analysis from the randomized, phase III HERO study versus leuprolide

Abstract

Although prostate cancer occurrence is relatively low in Asia, incidence and mortality have been rapidly increasing across the continent (Zhu et al. Nat Rev Urol 2021;18:282-301). In the global phase 3 HERO study, relugolix, the once-daily oral gonadotropin-releasing hormone receptor antagonist, demonstrated superior continuous suppression of testosterone to castrate levels through week 48 compared to leuprolide (relugolix:96.7% vs leuprolide:88.8%; difference:7.9% (95% confidence interval [CI], 4.1 to 11.8); Shore et al.